BE446238A - - Google Patents
Info
- Publication number
- BE446238A BE446238A BE446238DA BE446238A BE 446238 A BE446238 A BE 446238A BE 446238D A BE446238D A BE 446238DA BE 446238 A BE446238 A BE 446238A
- Authority
- BE
- Belgium
- Prior art keywords
- solution
- hemin
- blood
- gelatin
- hemoglobin
- Prior art date
Links
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 229940025294 hemin Drugs 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 150000002506 iron compounds Chemical class 0.000 description 4
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 239000000470 constituent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE446238A true BE446238A (enExample) |
Family
ID=102415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE446238D BE446238A (enExample) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE446238A (enExample) |
-
0
- BE BE446238D patent/BE446238A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keshavjee et al. | The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation | |
| Hamazaki et al. | Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients | |
| FR2488237A1 (fr) | Solution stabilisee d'oxydes de chlore | |
| BE1001209A3 (fr) | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. | |
| FR2832065A1 (fr) | Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations | |
| FR2530953A1 (fr) | Emulsion perfluoro-chimique utilisable comme sang artificiel et procede pour sa preparation | |
| FR2458285A1 (fr) | Preparation pharmaceutique transdermique au dinitrate d'isosorbide | |
| BE446238A (enExample) | ||
| Seven et al. | Influence of propylthiouracil treatment on oxidative stress and nitric oxide in Basedow disease patients | |
| Nitter‐Hauge | Poisoning with ethylene glycol monomethyl ether: report of two cases | |
| Kippen et al. | Effects of renal fuels on uptake of PAH and uric acid by separated renal tubules of the rabbit | |
| CA2283691A1 (fr) | Association therapeutique mineralo-vitaminique sous forme de preparation unitaire liquide buvable | |
| Soares de Moura et al. | Protective action of a hydroalcoholic extract of a vinifera grape skin on experimental preeclampsia in rats | |
| Zilversmit et al. | The preparation and use of anhydrous fat emulsions for intravenous feeding and metabolic experiments | |
| Williams et al. | Reanimation-less rapid recovery of a donor heart after circulatory death with prolonged 8-hour ischemic time | |
| Havard et al. | Open assessment of the effect of prazosin on plasma lipids | |
| Heard et al. | The perfusion of the adrenal gland with reference to the mechanism of adrenaline stabilisation | |
| LU85812A1 (fr) | Forme dosee d'etoposide a usage oral | |
| Ardalan et al. | Hypothyroidism-induced rhabdomyolysis and renal failure | |
| DEPRET et al. | Global energetic failure in brain-dead patients | |
| CA1275247C (fr) | Procede de solubilisation, au moment de l'emploi, d'un principe actiflipophile dans une solution aqueuse, en vue de son administration par voie intraveineuse | |
| EP0746325B1 (fr) | Gelee laxative hypocalorique a base d'huile de paraffine liquide et de lactulose, son procede de preparation | |
| FR2660552A1 (fr) | Nouveaux gels medicamenteux antiseptiques. | |
| Képinov | Système glycogénolytique hormonal: Sur le mécanisme de l'action glycogénolytique de l'adrenaline et le rôle de l'hormone hypophysaire dans ce mécanisme | |
| Kittikowit et al. | Lipid peroxidation and renal injury in renal ischemic reperfusion: effect of angiotensin inhibition |